Williamson to its board of directors, adding nearly three decades of neuroscience drug development, clinical research, and regulatory strategy experience to the clinical-stage biopharmaceutical company. According to a corporate press release issued by Vistagen, Williamson brings extensive leadership background in central nervous system (CNS) therapeutics to guide the firm’s pipeline.
Leadership Background and Industry Experience
Williamson currently operates as a CNS drug development consultant and serves as the founder of Destiny Biopharm Consulting. Prior to his current consulting work, he held the position of chief medical officer at QurAlis Corporation. His previous executive roles include serving as executive vice president and head of research and development at Acadia Pharmaceuticals Inc., where he directed the enterprise-wide research strategy.
According to corporate biographical records, Williamson also worked as chief medical officer at Avadel Pharmaceuticals and held senior leadership posts at H. Lundbeck A/S, including senior vice president and head of U.S. research and development, alongside deputy global chief medical officer. His career further includes a tenure as vice president and global head of therapeutic area leadership at Parexel International.
Neuropsychiatric Drug Approvals at Eli Lilly
During his time at Eli Lilly and Company, Williamson contributed to the clinical development and regulatory approvals of several major neuropsychiatric therapies. According to professional background details, his work at Eli Lilly included contributions to Symbyax, utilized for treatment-resistant depression and bipolar depression, and Zyprexa, indicated for the maintenance treatment of bipolar disorder.
Williamson previously sat on the board of directors for Bright Minds Biosciences, where he served on the compensation, audit, nomination, and corporate governance committees.
Vistagen’s Clinical Pipeline Focus
Vistagen develops late-stage clinical-phase biopharmaceutical product candidates delivered primarily through intranasal administration. According to the company’s development pipeline disclosures, the firm’s assets include fasedienol, which is currently undergoing Phase 3 clinical development for social anxiety disorder. Additional candidates include itruvone, advancing through Phase 2 development for major depressive disorder, and refisolone, targeted at vasomotor symptoms associated with menopause.
Related reading